Top Articles
Revised Stark and AKS Rules Are Good News for Labs
Federal regulators wanted to incorporate common definitions into both sets of regulations
CEO SUMMARY: It must be rewarding for federal rulemakers at the Centers for Medicare and Medicaid Services and the Office of the Inspector General to hear that attorneys representing clinical labs and pathology groups consider the new final rules for the Stark Law and the Anti-Kickb...
Understanding Key Parts of New AKS, Stark Law Rules
Certain revisions to both final federal rules should help clinical laboratories with compliance
CEO SUMMARY: Both the federal Stark Law and Anti-Kickback Statute have been revised and the final rules became effective on Jan. 19. The good news for clinical laboratories and anatomic pathology groups is that federal regulators from the Centers for Medicare and Medicaid Services a...
IVD & IT Update Roche to Acquire GenMark, Ovation.io Raises $21.5M
Roche to Pay $1.8 Billion for GenMark THERE'S MORE CONSOLIDATION in the in vitro diagnostics (IVD) industry. It was announced on Mar. 15 that Roche Diagnostics would acquire GenMa...
What Comes Next? Predictions on COVID-19 Test Volumes in 2021-22
Some public lab companies have good insights
CEO SUMMARY: Incoming data show that the number of referrals for both COVID-19 tests and routine tests is in a decline that started in October and is continuing. This complicates the strategic planning for hospital/health system labs, independent labs, and pathology groups. They nee...
IVD Update Truvian Sciences Raises $105M for Near-Patient Lab Test System
San Diego company hopes to obtain FDA clearance for its multi-analyte analyzer that uses drops of blood
DESPITE THE PANDEMIC, investors continue to support emerging in vitro diagnostics (IVD) companies. This is particularly true of start-up companies that want to develop clinical lab testing systems that can be used at the point of care, that require small amounts of blood, and that deliver accu...
Despite COVID-19, Regular Lab Testing Expands
TIMES ARE GOOD FOR THE REGULAR RANGE of clinical laboratory and anatomic pathology testing services. Despite the COVID-19 pandemic, the daily number of routine test specimens is near pre-pandemic levels and certain sectors of lab testing—particularly genetic tests and some high-cost assays—are showing substantial growth this year, compared to 2019....
Don’t Be at the Mercy of the Tumultuous Healthcare Revolution
Subscribe to The Dark Report for as little as $15.27 per week.
Get the most expert business intelligence for clinical laboratories and pathology groups available today. Subscribe to The Dark Report.
CURRENT ISSUE
Volume XXVIII, No. 4 – March 22, 2021
THERE’S POSITIVE NEWS FOR LABS on several fronts. For one, the daily number of routine test specimens is near pre-pandemic levels and certain sectors of lab testing—particularly genetic tests and some high-cost assays—are showing substantial growth this year, compared to 2019. Also, the Stark Law and AKS have been revised to make it easier for labs to comply.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.